PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33587348-0 2021 LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis. Imatinib Mesylate 52-60 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 119-123 34564697-4 2021 Here, we show that combining TKI (imatinib, nilotinib, dasatinib, or asciminib) treatment with the small-molecule MCL1 inhibitor S63845 exerted strong synergistic antiviability and proapoptotic effects on CML lines and CD34+ stem/progenitor cells isolated from untreated CML patients in chronic phase. Imatinib Mesylate 34-42 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 114-118 33587348-13 2021 MCL1 bound to miR-150-5p and reversed the effect of HULC on imatinib resistance. Imatinib Mesylate 60-68 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 0-4 33587348-15 2021 These findings indicated that HULC enhanced imatinib resistance in CML by modulating the miR-150-5p/MCL1 axis, providing a promising biomarker for CML. Imatinib Mesylate 44-52 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 100-104 32999756-0 2020 Expression differences of miR-142-5p between treatment-naive chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance. Imatinib Mesylate 128-136 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 193-197 30866043-7 2019 Cotreatment of neferine and imatinib significantly decreased the expression of BCR-ABL protein and its molecular chaperone heat shock protein 90 (Hsp90) mRNA and protein levels, and further decreased phospho-extracellular regulated protein kinase 1/2 (p-Erk1/2) and myeloid cell leukemia (Mcl-1) expression. Imatinib Mesylate 28-36 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 289-294 31349760-8 2019 The combination of MLN4924 and imatinib furthermore triggered a dramatic shift in the expression of MCL1 and NOXA. Imatinib Mesylate 31-39 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 100-104 26473951-6 2015 In KOSR-protected CML cells, imatinib still inhibited the BCR-ABL tyrosine kinase, reduced the phosphorylation of STAT, ERK and AKT, down-regulated BCL2, BCLxL, MCL1 and up-regulated BIM. Imatinib Mesylate 29-37 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 161-165 30205168-5 2018 Furthermore, OT-55 synergized with omacetaxine in imatinib-resistant KBM-5 R cells to inhibit the expression of Mcl-1, triggering apoptosis. Imatinib Mesylate 50-58 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 112-117 28319085-4 2017 These included the BCL2L1 and MCL1 combination, which was also effective in imatinib-resistant cells. Imatinib Mesylate 76-84 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 30-34 24947165-10 2014 CONCLUSIONS: Our study identifies anti-apoptotic effects of OPN that, through beta-catenin-mediated Mcl-1 up-regulation, significantly antagonized imatinib-induced apoptosis in GISTs. Imatinib Mesylate 147-155 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 100-105 24947165-11 2014 These results provide a potential rationale for therapeutic strategies targeting both OPN and Mcl-1 of the same anti-apoptotic signaling pathway, which may account for resistance to imatinib in GISTs. Imatinib Mesylate 182-190 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 94-99 24088895-9 2014 Sequential treatment with activin A and imatinib decreased Bcr-Abl, procaspase-3, Mcl-1, and Bcl-xL and also induced cleavage of procaspase-3/poly(ADP-ribose)polymerase. Imatinib Mesylate 40-48 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 82-87 22033489-5 2012 Combination of ABT-737 with imatinib (which decreases Mcl-1 levels) or triptolide (which decreases Mcl-1 and XIAP) synergistically induced death of both proliferating and quiescent CD34(+) progenitor cells obtained from TKI-resistant BC CML patients. Imatinib Mesylate 28-36 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 54-59 23613979-8 2013 Sequential treatment with ACM and imatinib induced Bcr-Abl down-regulation, cytochrome c release into the cytosol, and caspase-3 activation, as well as decreased Mcl-1 and Bcl-xL expressions, but did not affect Fas ligand/Fas death receptor and procaspase-8 expressions. Imatinib Mesylate 34-42 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 162-167 18088462-0 2007 [STI571 induces apoptosis of K562 cells through down-regulation of anti-apoptotic protein Mcl-1 and Bcl-xl expression]. Imatinib Mesylate 1-7 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 90-95 21220745-5 2011 We show that treatment of CLL cells with Abl-specific siRNA or with imatinib, to inhibit c-Abl activity, results in the down-regulation of Mcl-1 protein and mRNA. Imatinib Mesylate 68-76 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 139-144 21195056-4 2011 In imatinib mesylate-resistant K562 cells that displayed decreased BCR-ABL expression, bortezomib/SKI treatment markedly increased apoptosis and inhibited colony-formation in association with the downregulation of Mcl-1. Imatinib Mesylate 3-20 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 214-219 20153728-8 2010 Together, these data implicate Spred2 in imatinib-induced cytotoxicity in CML cells, possibly by inhibiting the Ras-ERK cascade and the pro-survival signaling molecules SPHK1 and Mcl-1. Imatinib Mesylate 41-49 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 179-184 18088462-8 2007 It is concluded that STI571 induces the apoptosis of CML cells by down-regulating the expressions of Mcl-1 and Bcl-xl, which suggests that Mcl-1 and Bcl-xl may play an important role in anti-apoptotic process of CML cells. Imatinib Mesylate 21-27 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 101-106 18088462-8 2007 It is concluded that STI571 induces the apoptosis of CML cells by down-regulating the expressions of Mcl-1 and Bcl-xl, which suggests that Mcl-1 and Bcl-xl may play an important role in anti-apoptotic process of CML cells. Imatinib Mesylate 21-27 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 139-144 15626746-0 2005 Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Imatinib Mesylate 138-146 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 18-23 17110460-8 2007 Moreover, MCL-1 ASOs were found to cooperate with various tyrosine kinase inhibitors in producing growth inhibition in neoplastic MCs, with synergistic effects observed with PKC412, AMN107, and imatinib in HMC-1.1 cells and with PKC412 in HMC-1.2 cells. Imatinib Mesylate 194-202 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 10-15 17926190-7 2007 Enhanced apoptosis, cytochrome C release, and caspase 3 cleavage as well as noticeable decrease of Mcl-1 and Bcl-XL were observed in K562 cells treated with both (-)gossypol and imatinib. Imatinib Mesylate 178-186 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 99-104 17595328-0 2007 The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Imatinib Mesylate 64-81 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 208-231 15626746-4 2005 The BCR/ABL inhibitor imatinib (=STI571) decreased the expression of MCL-1 in these cells. Imatinib Mesylate 22-30 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 69-74 15626746-4 2005 The BCR/ABL inhibitor imatinib (=STI571) decreased the expression of MCL-1 in these cells. Imatinib Mesylate 33-39 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 69-74 15626746-10 2005 Moreover, the mcl-1 ASO was found to synergize with imatinib in producing growth inhibition in these cells. Imatinib Mesylate 52-60 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 14-19 11782377-7 2002 Synergistic potentiation of STI571-mediated lethality by PD184352 was associated with multiple perturbations in signaling and apoptotic regulatory pathways, including caspase-dependent down-regulation of Bcr-Abl and Bcl-2; caspase-independent down-regulation of Bcl-x(L) and Mcl-1; activation of JNK, p38 MAPK, and p34(cdc2); and diminished phosphorylation of Stat5 and CREB. Imatinib Mesylate 28-34 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 275-280 12231544-5 2002 STI571/flavopiridol-mediated apoptosis was associated with the caspase-independent down-regulation of Bcl-x(L) and Mcl-1, activation of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase, and the caspase-dependent release of Smac/DIABLO and loss of deltapsi(m). Imatinib Mesylate 0-6 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 115-120